Hit enter to search or ESC to close

Author: Alterity Therapeutics

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity Therapeutics today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States. BioMUSE is a natural history study that aims to track the progression of patients with MSA, a Parkinsonian disorder without approved therapy.  The study is being conducted in collaboration with Vanderbilt University Medical ...

Alterity completes Placement Tranche 1 raising $10M

$25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of Placement raising $10M Tranche 2 completes on 18th November pending shareholder approval raising an additional $25M Alterity Therapeutics today lodged its Appendix 2A confirming the allocation and quotation of 271,251,007 shares as consideration under Tranche One of a $35M Placement to institutional ...

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches Tranche 1: $10M raised under Alterity’s current placement capacity Tranche 2: $25M subject to shareholder approval Attached 1.1 option under Tranche 2 The capital raising was cornerstone by top tier institutional investors in Australia and North America and supported by ...

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson’s Disease and Movement Disorders (MDS 2020) and the American Neurological Association’s 2020 Annual Meeting (ANA 2020). ...

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company’s lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. The company recently ...

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA).  Orphan Drug designation by the EC entitles Alterity to ten years of market exclusivity in the European Union for the ...

Alterity AGM Investor Conference Call

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference. The AGM is scheduled for 9:30 AM (Australian Eastern Daylight Time) Tuesday, November 26th, 2019 at the Adina Apartment Hotel, 189 Queen Street, Melbourne. Registration is from 9:15 AM. To ...